Triaminic Allerchews
This article was originally published in The Tan Sheet
Executive Summary
Upcoming late January launch of 10 mg loratadine quick-dissolve, wintergreen-flavored tablets under Triaminic children's cough/cold line may provide Novartis Consumer Healthcare's OTC unit with a strong start to 2004 sales. Triaminic Allerchews will debut in 8- and 24-count packages with substantial consumer and trade promotion support, Novartis says. The product will compete against Schering-Plough's Claritin Children's Formula Syrup, which contains 5 mg loratadine per dose (1"The Tan Sheet" July 28, 2003, p. 11)...
You may also be interested in...
Novartis CEO Calls Potential Schering-Plough Merger “Very Interesting”
A Novartis/Schering-Plough merger would increase Novartis' OTC portfolio by about 57% to $2.77 bil. and give the Swiss firm control over the formidable Claritin allergy and hives relief franchise
Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2
Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.